Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist. Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy. Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management. Consequently, the objective of this study were: * Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer * Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
correlation between Gleason score and dynamic parameters on PET and MRI
Timeframe: when anatomopathological report is available, an average of 3 months after the PET/CT